Multiple approaches converge on three biological subtypes of meningioma and extract new insights from published studies [RNA-Seq]

GSE189672Bayley et al., 2022

Baylor / Patel Lab three-subtype cohort

110 primary meningiomas profiled by both DNA methylation array and bulk RNA-seq, published as "Multiple approaches converge on three biological subtypes of meningioma and extract new insights from published studies" (PMID 35108039). A moderate-sized but cleanly matched multi-omic cohort. Every methylation sample has a corresponding RNA-seq sample from the same tumor, making it directly usable for methylation-expression integration analyses without needing to solve a sample-matching problem first.

Overview

Modality: Bulk RNA-seq
Sample count: 110
Patient count: 110
Institution: Baylor College of Medicine
Corresponding author: James C Bayley, Akash J Patel
Platform: Illumina HiSeq 4000 (GPL20301)
Access type: open
Tissue preservation: Not reported
WHO edition: Not reported
Ontology: Disease: MONDO:0016642 · Tissue: UBERON:0003547

Cohort detail

Grade breakdown: G1: 90 G2: 20 G3: 0
Sex distribution: 67 female, 43 male (n=110, from GSE189672_Clinical_data.xlsx Gender column)
Age distribution: n=110, range 19-81, mean 57.8 (from GSE189672_Clinical_data.xlsx Age column)
Anatomic location: n=110, from GSE189672_Clinical_data.xlsx Location column: Sphenoid Wing 20, Parafalcine 17, Anterior Skull Base 16, Frontal 13, Petroclival 10, Clival 9, Occipital 3, Frontal Convexity 3, Intraventricular 3, Cavernous Sinus/Middle Fossa 2, Foramen magnum 2, Cerebellar 2, Thoracic Spine 2, Tentorial/Cerebellar 1, Temporal 1, posterior fossa 1 (one row had a stray accent character, read as 'posterior fossa')
Brain invasion: 0 of 110 (all samples recorded 'N' for brain invasion in the deposited clinical table)
Normal/control tissue: None

Per-sample detail (110 samples)

Sample	Sex	Age	WHO grade	Diagnosis	Location	Treatment timing	Molecular subtype	Outcome
14-04	F	66	WHO I	Meningioma	Sphenoid Wing	primary	MenG A	Recurrence: N; Follow-up: 60.6 mo
15-17	F	69	WHO I	Meningioma	Sphenoid Wing	primary	MenG A	Recurrence: N; Follow-up: 37.0 mo
15-23	F	62	WHO I	Meningioma	Tentorial/Cerebellar	primary	MenG A	Recurrence: N; Follow-up: 57.9 mo
15-24	F	45	WHO I	Meningioma	Frontal	primary	MenG A	Recurrence: N; Follow-up: 0.0 mo
15-25	F	67	WHO I	Meningioma	Anterior Skull Base	primary	MenG A	Recurrence: N; Follow-up: 59.5 mo
15-32	M	69	WHO I	Meningioma	Sphenoid Wing	primary	MenG A	Recurrence: N; Follow-up: 57.0 mo
16-06	F	41	WHO I	Meningioma	Anterior Skull Base	primary	MenG A	Recurrence: N; Follow-up: 28.8 mo
16-35	M	75	WHO I	Meningioma	Anterior Skull Base	primary	MenG A	Recurrence: N; Follow-up: 37.5 mo
16-41	F	68	WHO I	Meningioma	Anterior Skull Base	primary	MenG A	Recurrence: N; Follow-up: 31.9 mo
16-44	M	68	WHO I	Meningioma	Sphenoid Wing	primary	MenG A	Recurrence: N; Follow-up: 46.7 mo
16-49	F	62	WHO I	Meningioma	Anterior Skull Base	primary	MenG A	Recurrence: N; Follow-up: 2.9 mo
17-02	M	61	WHO I	Meningioma	Anterior Skull Base	primary	MenG A	Recurrence: Y; Follow-up: 42.4 mo
17-03	F	58	WHO I	Meningioma	Anterior Skull Base	primary	MenG A	Recurrence: N; Follow-up: 6.8 mo
17-04	F	62	WHO I	Meningioma	Cavernous Sinus/Middle Fossa	primary	MenG A	Recurrence: N; Follow-up: 45.2 mo
17-13	M	68	WHO I	Meningioma	Frontal	primary	MenG A	Recurrence: N; Follow-up: 41.8 mo
17-15	M	79	WHO I	Meningioma	Clival	primary	MenG A	Recurrence: N; Follow-up: 42.1 mo
17-20	F	48	WHO I	Meningioma	Sphenoid Wing	primary	MenG A	Recurrence: N; Follow-up: 7.3 mo
17-22	F	47	WHO I	Meningioma	Anterior Skull Base	primary	MenG A	Recurrence: N; Follow-up: 33.8 mo
17-24	F	37	WHO I	Meningioma	Clival	primary	MenG A	Recurrence: N; Follow-up: 23.5 mo
17-25	F	45	WHO I	Meningioma	Occipital	primary	MenG A	Recurrence: N; Follow-up: 31.2 mo
17-28	F	48	WHO I	Meningioma	Anterior Skull Base	primary	MenG A	Recurrence: N; Follow-up: 29.1 mo
17-33	F	78	WHO I	Meningioma	Petroclival	primary	MenG A	Recurrence: Y; Follow-up: 21.5 mo
17-35	F	58	WHO I	Meningioma	Parafalcine	primary	MenG A	Recurrence: N; Follow-up: 14.3 mo
18-03	M	72	WHO I	Meningioma	Parafalcine	primary	MenG A	Recurrence: N; Follow-up: 19.1 mo
18-05	F	46	WHO I	Meningioma	Sphenoid Wing	primary	MenG A	Recurrence: Y; Follow-up: 14.0 mo
18-07	F	58	WHO I	Meningioma	Sphenoid Wing	primary	MenG A	Recurrence: N; Follow-up: 0.1 mo
18-14	F	67	WHO I	Meningioma	Frontal Convexity	primary	MenG A	Recurrence: N; Follow-up: 0.0 mo
18-15	F	74	WHO I	Meningioma	Parafalcine	primary	MenG A	Recurrence: N; Follow-up: 5.6 mo
18-17	F	42	WHO I	Meningioma	Cavernous Sinus/Middle Fossa	primary	MenG A	Recurrence: N; Follow-up: 23.1 mo
18-18	F	60	WHO I	Meningioma	Clival	primary	MenG A	Recurrence: N; Follow-up: 18.4 mo
18-20	F	41	WHO I	Meningioma	Sphenoid Wing	primary	MenG A	Recurrence: Y; Follow-up: 19.6 mo
18-26	F	68	WHO I	Meningioma	Anterior Skull Base	primary	MenG A	Recurrence: N; Follow-up: 16.3 mo
18-28	F	76	WHO I	Meningioma	Occipital	primary	MenG A	Recurrence: N; Follow-up: 0.0 mo
18-29	F	32	WHO I	Meningioma	Sphenoid Wing	primary	MenG A	Recurrence: N; Follow-up: 18.5 mo
18-30	M	21	WHO I	Meningioma	Anterior Skull Base	primary	MenG A	Recurrence: N; Follow-up: 5.1 mo
18-35	M	35	WHO I	Meningioma	Anterior Skull Base	primary	MenG A	Recurrence: N; Follow-up: 5.6 mo
18-39	F	58	WHO I	Meningioma	Petroclival	primary	MenG A	Recurrence: N; Follow-up: 20.8 mo
18-49	M	69	WHO I	Meningioma	Anterior Skull Base	primary	MenG A	Recurrence: N; Follow-up: 20.2 mo
18-50	F	75	WHO I	Meningioma	Clival	primary	MenG A	Recurrence: N; Follow-up: 21.8 mo
20-22	M	38	WHO II	Meningioma	Parafalcine	primary	MenG A	Recurrence: N; Follow-up: 1.2 mo
20-28	F	54	WHO I	Meningioma	Petroclival	primary	MenG A	Recurrence: N; Follow-up: 0.1 mo
20-48	M	73	WHO I	Meningioma	Foramen magnumá	primary	MenG A	Recurrence: N; Follow-up: 0.1 mo
DCC07	F	66	WHO I	Meningioma	Anterior Skull Base	primary	MenG A	Recurrence: N; Follow-up: 86.4 mo
DCC12	F	66	WHO II	Meningioma	Frontal	primary	MenG A	Recurrence: N; Follow-up: 55.8 mo
DCC25	M	56	WHO I	Meningioma	Sphenoid Wing	primary	MenG A	Recurrence: Y; Follow-up: 78.8 mo
DCC28	F	63	WHO I	Meningioma	Frontal	primary	MenG A	Recurrence: N; Follow-up: 78.3 mo
DCC29	M	59	WHO I	Meningioma	Sphenoid Wing	primary	MenG A	Recurrence: N; Follow-up: 32.4 mo
DCC30	F	62	WHO I	Meningioma	Frontal	primary	MenG A	Recurrence: N; Follow-up: 67.1 mo
DCC33	M	33	WHO I	Meningioma	Intraventricular	primary	MenG A	Recurrence: N; Follow-up: 0.1 mo
DCC34	M	60	WHO II	Meningioma	Frontal	primary	MenG A	Recurrence: N; Follow-up: 22.0 mo
DCC37	M	59	WHO II	Meningioma	Temporal	primary	MenG A	Recurrence: N; Follow-up: 89.4 mo
DCC51	F	54	WHO I	Meningioma	Sphenoid Wing	primary	MenG A	Recurrence: N; Follow-up: 49.5 mo
15-18	F	58	WHO I	Meningioma	Petroclival	primary	MenG B	Recurrence: N; Follow-up: 38.7 mo
16-14	F	42	WHO I	Meningioma	Cerebellar	primary	MenG B	Recurrence: N; Follow-up: 49.7 mo
16-47	F	81	WHO I	Meningioma	Parietal	primary	MenG B	Recurrence: N; Follow-up: 12.4 mo
16-50	M	57	WHO I	Meningioma	Cerebellar	primary	MenG B	Recurrence: N; Follow-up: 6.1 mo
17-05	F	63	WHO I	Meningioma	Parafalcine	primary	MenG B	Recurrence: N; Follow-up: 6.0 mo
17-08	F	68	WHO I	Meningioma	Parietal	primary	MenG B	Recurrence: N; Follow-up: 45.7 mo
17-11	F	39	WHO I	Meningioma	Petroclival	primary	MenG B	Recurrence: Y; Follow-up: 40.1 mo
17-12	F	61	WHO I	Meningioma	Thoracic Spine	primary	MenG B	Recurrence: N; Follow-up: 31.7 mo
17-19	F	51	WHO I	Meningioma	Sphenoid Wing	primary	MenG B	Recurrence: N; Follow-up: 23.2 mo
17-29	M	26	WHO I	Meningioma	Clival	primary	MenG B	Recurrence: N; Follow-up: 34.8 mo
18-38	M	57	WHO II	Meningioma	Frontal	primary	MenG B	Recurrence: N; Follow-up: 0.0 mo
18-40	F	65	WHO I	Meningioma	Clival	primary	MenG B	Recurrence: N; Follow-up: 24.3 mo
18-41	M	62	WHO I	Meningioma	Clival	primary	MenG B	Recurrence: N; Follow-up: 11.1 mo
18-45	M	59	WHO I	Meningioma	Parafalcine	primary	MenG B	Recurrence: N; Follow-up: 18.4 mo
20-27	M	50	WHO II	Meningioma	posterior fosaá	primary	MenG B	Recurrence: N; Follow-up: 0.9 mo
20-39	F	78	WHO I	Meningioma	Parafalcine	primary	MenG B	Recurrence: N; Follow-up: 0.5 mo
20-50	M	19	WHO I	Meningioma	Foramen magnumá	primary	MenG B	Recurrence: N; Follow-up: 0.0 mo
DCC09	F	66	WHO I	Meningioma	Petroclival	primary	MenG B	Recurrence: N; Follow-up: 55.2 mo
DCC10	M	72	WHO II	Meningioma	Parafalcine	primary	MenG B	Recurrence: N; Follow-up: 60.6 mo
DCC18	F	52	WHO I	Meningioma	Petroclival	primary	MenG B	Recurrence: N; Follow-up: 33.1 mo
DCC19	F	50	WHO I	Meningioma	Parafalcine	primary	MenG B	Recurrence: N; Follow-up: 75.3 mo
DCC22	F	57	WHO II	Meningioma	Sphenoid Wing	primary	MenG B	Recurrence: Y; Follow-up: 24.9 mo
DCC27	F	28	WHO I	Meningioma	Frontal	primary	MenG B	Recurrence: N; Follow-up: 11.2 mo
DCC31	M	64	WHO II	Meningioma	Parafalcine	primary	MenG B	Recurrence: N; Follow-up: 45.2 mo
DCC36	F	48	WHO II	Meningioma	Sphenoid Wing	primary	MenG B	Recurrence: N; Follow-up: 78.5 mo
DCC53	F	59	WHO I	Meningioma	Petroclival	primary	MenG B	Recurrence: N; Follow-up: 49.4 mo
16-02	F	68	WHO I	Meningioma	Sphenoid Wing	primary	MenG C	Recurrence: Y; Follow-up: 52.3 mo
16-28	M	49	WHO I	Meningioma	Petroclival	primary	MenG C	Recurrence: Y; Follow-up: 37.4 mo
17-01	M	58	WHO I	Meningioma	Parafalcine	primary	MenG C	Recurrence: Y; Follow-up: 23.5 mo
17-09	F	68	WHO II	Meningioma	Intraventricular	primary	MenG C	Recurrence: N; Follow-up: 45.7 mo
17-30	M	59	WHO II	Meningioma	Parietal	primary	MenG C	Recurrence: Y; Follow-up: 25.5 mo
18-13	M	81	WHO I	Meningioma	Sphenoid Wing	primary	MenG C	Recurrence: N; Follow-up: 0.0 mo
18-24	M	77	WHO II	Meningioma	Frontal Convexity	primary	MenG C	Recurrence: Y; Follow-up: 22.5 mo
18-33	F	42	WHO I	Meningioma	Clival	primary	MenG C	Recurrence: N; Follow-up: 15.9 mo
18-34	F	33	WHO I	Meningioma	Parafalcine	primary	MenG C	Recurrence: Y; Follow-up: 21.1 mo
18-42	F	75	WHO II	Meningioma	Frontal	primary	MenG C	Recurrence: Y; Follow-up: 20.3 mo
18-43	M	65	WHO II	Meningioma	Frontal	primary	MenG C	Recurrence: Y; Follow-up: 11.4 mo
18-48	F	64	WHO II	Meningioma	Frontal	primary	MenG C	Recurrence: N; Follow-up: 18.7 mo
20-11	F	51	WHO I	Meningioma	Anterior Skull Base	primary	MenG C	Recurrence: N; Follow-up: 0.0 mo
20-26	F	72	WHO I	Meningioma	Parafalcine	primary	MenG C	Recurrence: N; Follow-up: 7.2 mo
DCC06	M	53	WHO II	Meningioma	Frontal	primary	MenG C	Recurrence: N; Follow-up: 76.9 mo
DCC13	F	47	WHO I	Meningioma	Intraventricular	primary	MenG C	Recurrence: N; Follow-up: 31.7 mo
DCC21	F	43	WHO II	Meningioma	Parietal	primary	MenG C	Recurrence: Y; Follow-up: 96.5 mo
DCC23	M	61	WHO I	Meningioma	Parietal	primary	MenG C	Recurrence: N; Follow-up: 0.0 mo
DCC32	M	58	WHO I	Meningioma	Parafalcine	primary	MenG C	Recurrence: N; Follow-up: 0.0 mo
DCC38	M	78	WHO I	Meningioma	Parafalcine	primary	MenG C	Recurrence: N; Follow-up: 60.5 mo
DCC40	M	38	WHO II	Meningioma	Parafalcine	primary	MenG C	Recurrence: Y; Follow-up: 26.2 mo
DCC43	M	70	WHO I	Meningioma	Occipital	primary	MenG C	Recurrence: N; Follow-up: 22.2 mo
15-13	M	78	WHO I	Meningioma	Petroclival	primary	Unknown	Recurrence: Y; Follow-up: 17.5 mo
15-35	F	60	WHO I	Meningioma	Parafalcine	primary	Unknown	Recurrence: N; Follow-up: 0.0 mo
16-51	M	75	WHO I	Meningioma	Anterior Skull Base	primary	Unknown	Recurrence: N; Follow-up: 23.1 mo
17-10	M	50	WHO I	Meningioma	Sphenoid Wing	primary	Unknown	Recurrence: N; Follow-up: 0.0 mo
17-23	F	68	WHO I	Meningioma	Clival	primary	Unknown	Recurrence: N; Follow-up: 41.9 mo
17-34	F	40	WHO I	Meningioma	Sphenoid Wing	primary	Unknown	Recurrence: Y; Follow-up: 30.8 mo
18-08	M	73	WHO I	Meningioma	Thoracic Spine	primary	Unknown	Recurrence: N; Follow-up: 5.3 mo
20-18	F	71	WHO I	Meningioma	Frontal Convexity	primary	Unknown	Recurrence: N; Follow-up: 0.0 mo
DCC35	M	47	WHO II	Meningioma	Frontal	primary	Unknown	Recurrence: N; Follow-up: 94.6 mo
DCC42	F	33	WHO I	Meningioma	Sphenoid Wing	primary	Unknown	Recurrence: N; Follow-up: 36.7 mo

Priority attributes

WHO grade breakdown availableLinked to other modalitiesLarge cohort (top quartile)Molecular subtype annotatedOutcome/survival dataPeer-reviewed

Publications

Bayley JC 5th, et al. Multiple approaches converge on three biological subtypes of meningioma and extract new insights from published studies. Science advances, 2022. PMID 35108039 · DOI

Related datasets

Multiple approaches converge on three biological subtypes of meningioma and extract new insights from published studies [Methylation array] →

Also related: GSE189673

Sources

GEO
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE189672
PubMed
https://pubmed.ncbi.nlm.nih.gov/35108039/
GEO
https://ftp.ncbi.nlm.nih.gov/geo/series/GSE189nnn/GSE189672/suppl/GSE189672_Clinical_data.xlsx
PMC full text
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11313601/